Undisclosed TDP-43 inhibitor / BMS, Prothena - LARVOL DELTA

Prothena Announces Poster Presentation on its TDP-43 CYTOPE Program at Neuroscience 2025 (Businesswire) - "TDP-43 CYTOPE preclinical data demonstrates the potential of Prothena’s CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targeting of intracellular disease pathways. Systemically-administered TDP-43 CYTOPE rapidly and efficiently distributed to the brain and periphery, internalized into the cytosol and significantly reduced intracellular TDP-43 pathology in an ALS mouse model."

Preclinical • Amyotrophic Lateral Sclerosis